| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Tuesday, April 02, 2019 10:50:41 AM
Bb..
Quote: "Can you share your opinion on SOC and malpractice?"
Yes.. SOC in Medicine is a legal term relating to negligence...Negligence does not imply perfection,it refers in "med-mal" to the idea of taking the necessary safety precautions that a competent physician would take. And provide medications and procedures that offer the patient the greatest therapeutic benefit available in a given clinical situation..(my words).
Malpractice is defined as practicing below the Standard of Care...This is in most cases relatively easy to determine as the physicians is careless and fails to take proper steps omitting the necessary or lacking the knowledge to treat the condition correctly...In reality things are often much more complicated ...and juries tend to consider the health and financial losses the patient has suffered and award accordingly and not so much the actions of the physician.
The SOC obviously brings into question the importance of what the authorities consider safe and effective...And some practical considerations..including cost benefits..
The issue here is FDA is considered the ultimate authority on safety and efficacy as far as drugs and devices are concerned..And this authority is given by congress..Whether or not FDA "practices medicine" is open to debate..As a general rule and in almost all cases FDA grants approval of a drug for a given indication by issuing a drug label which lists therapeutic benefits and safety concerns...It is true indidual doctors can and are encouraged by FDA to use drugs "Off Label" (OL) for other indications...But neither they nor the company that manufactures the drug can market these drugs for the OT conditions without FDA approval. And that is why we are waiting for the sNDA label change...
I'm not sure a drug which is not approved by FDA for the indication and is being used Off Label...can be considered SOC..(Please don't go bonkers...I'm not giving an opinion..I'm confessing I'm confused.)
So I don't know how this ADA pronouncement that V is SOC for T2DM, on statins, at CVD risk and moderately high trigs...Will sit with FDA..Obviously as a guy with an obscene amount of money and shares in Amarin...I hope it becomes law of the land tomorrow...The same for the PR in Canada...I hope with all the rest of you that FDA just realizes it is not keeping up with medical reality and says nothing and joins the party...I do think FDA will expedite The PR decision in Amarin's favor..and grant the sNDA in record time...
":>) JL
Quote: "Can you share your opinion on SOC and malpractice?"
Yes.. SOC in Medicine is a legal term relating to negligence...Negligence does not imply perfection,it refers in "med-mal" to the idea of taking the necessary safety precautions that a competent physician would take. And provide medications and procedures that offer the patient the greatest therapeutic benefit available in a given clinical situation..(my words).
Malpractice is defined as practicing below the Standard of Care...This is in most cases relatively easy to determine as the physicians is careless and fails to take proper steps omitting the necessary or lacking the knowledge to treat the condition correctly...In reality things are often much more complicated ...and juries tend to consider the health and financial losses the patient has suffered and award accordingly and not so much the actions of the physician.
The SOC obviously brings into question the importance of what the authorities consider safe and effective...And some practical considerations..including cost benefits..
The issue here is FDA is considered the ultimate authority on safety and efficacy as far as drugs and devices are concerned..And this authority is given by congress..Whether or not FDA "practices medicine" is open to debate..As a general rule and in almost all cases FDA grants approval of a drug for a given indication by issuing a drug label which lists therapeutic benefits and safety concerns...It is true indidual doctors can and are encouraged by FDA to use drugs "Off Label" (OL) for other indications...But neither they nor the company that manufactures the drug can market these drugs for the OT conditions without FDA approval. And that is why we are waiting for the sNDA label change...
I'm not sure a drug which is not approved by FDA for the indication and is being used Off Label...can be considered SOC..(Please don't go bonkers...I'm not giving an opinion..I'm confessing I'm confused.)
So I don't know how this ADA pronouncement that V is SOC for T2DM, on statins, at CVD risk and moderately high trigs...Will sit with FDA..Obviously as a guy with an obscene amount of money and shares in Amarin...I hope it becomes law of the land tomorrow...The same for the PR in Canada...I hope with all the rest of you that FDA just realizes it is not keeping up with medical reality and says nothing and joins the party...I do think FDA will expedite The PR decision in Amarin's favor..and grant the sNDA in record time...
":>) JL
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
